Financial results for the period ended September 30, 2026
As filed · Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
What happened
FactFinancial results for the period ended September 30, 2026. Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026. Limited Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Order Book
DelayedWe are pleased with our FY25 performance, which underscores the strength of our strategy and execution.
Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting from now.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting (management committed by FY29)
- Starting with a revenue base of Rs.53 crores, we are targeting Rs.10 crores EBITDA by year two post-integratio (management committed by FY27)
Evidence
- Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%